Home › Funds › Stonepine Capital Management, LLC › XERS
Stonepine Capital Management, LLC position in XERS
XERIS BIOPHARMA HOLDINGS INC · Health Care
Stonepine Capital Management, LLC reported holding 280,000 shares of XERS (XERIS BIOPHARMA HOLDINGS INC) in its Q2 2026 13F filing — a position valued at US$2.1M, representing 1.39% of its reported portfolio and ranking #24 among its reported holdings. Stonepine Capital Management, LLC has disclosed XERS holdings in 8 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's XERS position evolved
Stonepine Capital Management, LLC first disclosed a stake in XERS in Q3 2023 at 5,915,372 shares (US$11.0M). The position peaked in Q4 2023 at 5,937,000 shares, worth US$14.0M. Across 8 filings, Stonepine Capital Management, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 280,000 shares valued at US$2.1M — an increase of 239,970 shares quarter over quarter.. Notable position changes include a 90% trim in Q1 2024 (shares rose 2% over the following quarter), a 101% increase in Q2 2025 (shares rose 74% over the following quarter), a 599% increase in Q2 2026 (shares rose 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.92M | $11.00M | New |
| Q4 2023 | 5.94M | $13.95M | Hold |
| Q1 2024 | 598.09K | $1.32M | Reduce |
| Q4 2024 | 182.32K | $618.05K | New |
| Q1 2025 | 102.27K | $561.43K | Reduce |
| Q2 2025 | 205.10K | $957.82K | Add |
| Q1 2026 | 40.03K | $232.17K | New |
| Q2 2026 | 280.00K | $2.10M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XERS and 13F data
XERS (XERIS BIOPHARMA HOLDINGS INC) is a Health Care company. 53 other funds we track also report a position in XERS — the largest reported positions include CAPSTONE INVESTMENT ADVISORS, LLC (US$62.6M), Polar Asset Management Partners Inc. (US$28.8M), Rosalind Advisors, Inc. (US$23.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XERS
- CAPSTONE INVESTMENT ADVISORS, LLC 23.07M sh · $62.64M · Q2 2026
- Polar Asset Management Partners Inc. 10.50M sh · $28.80M · Q2 2026
- Rosalind Advisors, Inc. 2.91M sh · $23.04M · Q2 2026
- Parkman Healthcare Partners LLC 1.81M sh · $14.32M · Q2 2026
- Vilga Financial Planning LLC 1.06M sh · $10.13M · Q3 2026
- Ishara Investments LP 1.23M sh · $9.74M · Q2 2026
- Knott David M Jr 1.06M sh · $8.40M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 693.26K sh · $6.63M · Q3 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held XERS?
Stonepine Capital Management, LLC has disclosed XERS holdings in 8 of the last 12 reported quarters, going back to Q3 2023.
What is Stonepine Capital Management, LLC's current position in XERS?
As of Q2 2026, Stonepine Capital Management, LLC holds 280.00K shares of XERS (XERIS BIOPHARMA HOLDINGS INC), valued at $2.10M, representing 1.39% of its reported portfolio and ranking #24.
Has Stonepine Capital Management, LLC been buying or selling XERS?
In the latest 13F filing (Q2 2026), Stonepine Capital Management, LLC increased its position in XERS. The position peaked in Q4 2023 at 5.94M shares.
Which other funds hold XERS?
Other major institutional holders of XERS include CAPSTONE INVESTMENT ADVISORS, LLC, Polar Asset Management Partners Inc., Rosalind Advisors, Inc., among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.